Prof Nicoletta Colombo speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the recent data on the use of immunotherapy in cervical and endometrial cancers.

She states there are several phase II trials that have achieved a response rate of close to 50 percent in patients with MSI high tumours when treated with immune checkpoint inhibitors.

Prof Colombo believes this field is heading towards the use of combination approaches and describes some ongoing phase III trials that are investigating the combination of immune checkpoint inhibitors.